Phage Therapy in Germany-Update 2023

  1. Willy, Christian ORCID logo
  2. Bugert, Joachim J.
  3. Claßen, Annika Yanina ORCID logo
  4. Lin, Ching-Yi ORCID logo
  5. Düchting, Anja
  6. Gross, Justus ORCID logo
  7. Hammerl, Jens Andre ORCID logo
  8. Korf, Imke ORCID logo
  9. Kühn, Christian
  10. Lieberknecht-Jouy, Simone
  11. Rohde, Christine
  12. Rupp, Markus
  13. Vehreschild, Maria J. G. T.
  14. Vogele, Kilian ORCID logo
  15. Wienecke, Sarah
  16. Witzenrath, Martin ORCID logo
  17. Würstle, Silvia ORCID logo
  18. Ziehr, Holger
  19. moelling, karin ORCID logo
  20. Broecker, Felix

Download
53_viruses-15-00588-v2.pdf 1,07MB
WeightNameValue
1000 Titel
  • Phage Therapy in Germany-Update 2023
1000 Autor/in
  1. Willy, Christian |
  2. Bugert, Joachim J. |
  3. Claßen, Annika Yanina |
  4. Lin, Ching-Yi |
  5. Düchting, Anja |
  6. Gross, Justus |
  7. Hammerl, Jens Andre |
  8. Korf, Imke |
  9. Kühn, Christian |
  10. Lieberknecht-Jouy, Simone |
  11. Rohde, Christine |
  12. Rupp, Markus |
  13. Vehreschild, Maria J. G. T. |
  14. Vogele, Kilian |
  15. Wienecke, Sarah |
  16. Witzenrath, Martin |
  17. Würstle, Silvia |
  18. Ziehr, Holger |
  19. moelling, karin |
  20. Broecker, Felix |
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-02-20
1000 Erschienen in
1000 Quellenangabe
  • 15(2):588
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3390/v15020588 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960545/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Bacteriophage therapy holds promise in addressing the antibiotic-resistance crisis, globally and in Germany. Here, we provide an overview of the current situation (2023) of applied phage therapy and supporting research in Germany. The authors, an interdisciplinary group working on patient-focused bacteriophage research, addressed phage production, phage banks, susceptibility testing, clinical application, ongoing translational research, the regulatory situation, and the network structure in Germany. They identified critical shortcomings including the lack of clinical trials, a paucity of appropriate regulation and a shortage of phages for clinical use. Phage therapy is currently being applied to a limited number of patients as individual treatment trials. There is presently only one site in Germany for large-scale good-manufacturing-practice (GMP) phage production, and one clinic carrying out permission-free production of medicinal products. Several phage banks exist, but due to varying institutional policies, exchange among them is limited. The number of phage research projects has remarkably increased in recent years, some of which are part of structured networks. There is a demand for the expansion of production capacities with defined quality standards, a structured registry of all treated patients and clear therapeutic guidelines. Furthermore, the medical field is still poorly informed about phage therapy. The current status of non-approval, however, may also be regarded as advantageous, as insufficiently restricted use of phage therapy without adequate scientific evidence for effectiveness and safety must be prevented. In close coordination with the regulatory authorities, it seems sensible to first allow some centers to treat patients following the Belgian model. There is an urgent need for targeted networking and funding, particularly of translational research, to help advance the clinical application of phages.
1000 Sacherschließung
lokal regulatory framework
lokal Germany
lokal phage therapy
lokal antimicrobial resistance
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9604-3384|https://frl.publisso.de/adhoc/uri/QnVnZXJ0LCBKb2FjaGltIEouIA==|https://orcid.org/0000-0003-2905-5139|https://orcid.org/0000-0003-0663-0225|https://frl.publisso.de/adhoc/uri/RMO8Y2h0aW5nLCBBbmphIA==|https://orcid.org/0000-0002-3281-7512|https://orcid.org/0000-0002-6930-4358|https://orcid.org/0000-0001-6073-9307|https://frl.publisso.de/adhoc/uri/S8O8aG4sIENocmlzdGlhbiA=|https://frl.publisso.de/adhoc/uri/TGllYmVya25lY2h0LUpvdXksIFNpbW9uZSA=|https://frl.publisso.de/adhoc/uri/Um9oZGUsIENocmlzdGluZSA=|https://frl.publisso.de/adhoc/uri/UnVwcCwgTWFya3VzIA==|https://frl.publisso.de/adhoc/uri/VmVocmVzY2hpbGQsIE1hcmlhIEouIEcuIFQuIA==|https://orcid.org/0000-0003-0643-5622|https://frl.publisso.de/adhoc/uri/V2llbmVja2UsIFNhcmFoIA==|https://orcid.org/0000-0002-9787-5633|https://orcid.org/0000-0003-0787-3894|https://frl.publisso.de/adhoc/uri/WmllaHIsIEhvbGdlciA=|https://orcid.org/0000-0003-3265-8408|https://frl.publisso.de/adhoc/uri/QnJvZWNrZXIsIEZlbGl4
1000 Label
1000 Förderer
  1. Bundesagentur für Sprunginnovationen GmbH |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Phage Therapy in Germany-Update 2023
    Phage Therapy in Germany-Update 2023
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Bundesagentur für Sprunginnovationen GmbH |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6447490.rdf
1000 Erstellt am 2023-05-03T14:45:44.749+0200
1000 Erstellt von 280
1000 beschreibt frl:6447490
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-05-05T10:23:13.656+0200
1000 Objekt bearb. Fri May 05 07:36:04 CEST 2023
1000 Vgl. frl:6447490
1000 Oai Id
  1. oai:frl.publisso.de:frl:6447490 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source